Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Santaris and miRagen Expand Partnership in the Field of Drugs Against microRNAs

Published: Wednesday, January 16, 2013
Last Updated: Wednesday, January 16, 2013
Bookmark and Share
miRagen receives license to develop a further six LNA drugs.

Under the expanded agreement, miRagen obtains a broad non-exclusive license in the miRNA therapeutics field for therapeutics research and world-wide exclusive rights to research, develop and commercialize LNA drugs against up to six additional microRNA targets that have been shown to be important in human disease areas of high unmet need. This brings the total number of microRNA targets under the agreement to ten. Santaris Pharma A/S will receive a combination of cash and equity in consideration for the licenses as well as clinical milestones and royalties on products emerging from the alliance. Financial terms were not disclosed.

Henrik Ørum, CSO and VP, Business Development at Santaris Pharma A/S stated:  “Our collaboration with miRagen is an important part of our corporate strategy in the microRNA therapeutics field, so we are very pleased with our collective decision to expand the relationship. MicroRNA therapy is an exciting new branch of human medicine where the LNA drug platform has already provided proof-of-concept in phase2 clinical studies in HCV patient using Santaris´miRNA-122 inhibitor, Miravirsen.”

William S. Marshall, President and CEO of miRagen stated: “Our partnership with Santaris has been very productive, and we are excited to expand the relationship to additional microRNA targets in our portfolio. Our goal is to identify important disease causing microRNAs and to deploy the world’s best technologies to create therapeutic development candidates against diseases with high unmet medical need. We hope these new programs will translate into novel drugs that will help patients suffering from serious diseases live longer and better lives.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Santaris Pharma Partners with Bristol-Myers Squibb
Santaris Pharma announces a worldwide discovery alliance with Bristol-Myers Squibb to discover and develop novel RNA-targeted medicines.
Wednesday, April 24, 2013
LNA-based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit
Santaris Pharma’s EZN-2968 was well tolerated and showed clinical benefit in previously treated cancer patients with advanced malignancies.
Tuesday, June 16, 2009
Santaris Delivers Six LNA-Based RNA Inhibitors to Enzon Ahead of Schedule
Santaris announces completion of the delivery of six cancer target drug candidates to its collaboration partner Enzon.
Tuesday, April 28, 2009
Santaris Pharma Begins Human Clinical Testing of the World’s First Medicine Targeted at a Human microRNA
SPC3649 (LNA-antimiR-122) being developed as a potential new therapy for Hepatitis C virus (HCV) infection.
Wednesday, May 28, 2008
Nature Publishes Study by Santaris Pharma Scientists and Collaborators
The paper demonstrates microRNA silencing in non-human primates, providing a validation of Santaris Pharma’s clinical program to develop a LNA-based therapeutics.
Friday, March 28, 2008
Santaris Pharma’s HIF-1 Alpha Antagonist Begins Second Phase 1 Study against Solid Tumours and Lymphoma
The Company’s collaboration partner Enzon Pharmaceuticals has initiated a second clinical study of EZN-2968 to evaluate additional dosing schedule.
Monday, November 05, 2007
Santaris Pharma Awarded €1.35M by Denmark’s Advanced Technology Foundation
Santaris Pharma has been awarded the grant towards the development of the first ever drug targeted against a human microRNA.
Wednesday, July 04, 2007
Santaris Pharma Raises EUR 40 M of new Equity
The funds will enable the further development of Santaris Pharma’s platform for LNA-based human therapeutics.
Friday, March 17, 2006
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!